| Title | An analytical study of drug utilization, disease progression, and adverse events among 165 COVID-19 patients |
| Authors | Sun, Feng Kou, Hao Wang, Shengfeng Lu, Yun Zhao, Houyu Li, Wenjing Zhou, Qingxin Jiang, Qiaoli Cheng, Yinchu Yang, Kun Zhuo, Lin Xu, Yang Wu, Dongfang Zhan, Siyan Cheng, Hong |
| Affiliation | Wuhan Univ, Dept Pharm, Zhongnan Hosp, 169 Donghu Rd, Wuhan 430071, Peoples R China Peking Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 38 Xueyuan Rd, Beijing 100191, Peoples R China Peking Univ Third Hosp, Dept Pharm, Beijing, Peoples R China Peking Univ Third Hosp, Res Ctr Clin Epidemiol, Beijing, Peoples R China Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden |
| Keywords | 2019-NCOV OUTBREAK |
| Issue Date | Feb-2021 |
| Publisher | ANNALS OF TRANSLATIONAL MEDICINE |
| Abstract | Background: The coronavirus disease 2019 (COVID-19) epidemic has lasted for nearly 4 months by this study was conducted. We aimed to describe drug utilization, disease progression, and adverse drug events of COVID-19. Methods: A retrospective, single-center case series study enrolled 165 consecutive hospitalized COVID-19 patients who were followed up until March 25, 2020, from a designated hospital in Wuhan. Patients were grouped by a baseline degree of severity: non-severe and severe. An analytical study of drug utilization, disease progression, and adverse events (AEs) of COVID-19 was conducted. Results: Of the 165 COVID-19 cases, antivirals, antibacterials, glucocorticoids, and traditional Chinese medicine (TCM) were administered to 92.7%, 98.8%, 68.5%, and 55.2% of patients, respectively. The total kinds of drugs administered to the severe subgroup [26, interquartile range (IQR) 18-39] were 11 more than the non-severe subgroup (15, IQR 10-24), regardless of comorbidities. The 2 most common combinations of medications in the 165 cases were `antiviral therapy + glucocorticoids + TCM' (81, 49.1%) and `antiviral therapy + glucocorticoids' (23, 13.9%). Compared with non- severe cases, severe cases received more glucocorticoids (88.5% vs. 66.2%, P=0.02), but less TCM (50.0% vs. 63.3%, P=0.20), and suffered a higher percentage of death (34.6% vs. 7.2%, P=0.001). At the end of the follow-up, 130 (78.8%) patients had been discharged, and 24 (14.5%) died. There were 13 patients (7.9%) who had elevated liver enzymes, and 49 patients (29.7%) presented with worsening kidney function during the follow-up. Conclusions: Of the 165 COVID-19 patients, the fatality rate remained high (14.5%). Drug utilization for COVID-19 was diverse and generally complied with the existing guidelines. Combination regimens containing antiviral drugs might be beneficial to assist COVID-19 recovery. Additionally, liver and kidney AEs should not be ignored. |
| URI | http://hdl.handle.net/20.500.11897/623689 |
| ISSN | 2305-5839 |
| DOI | 10.21037/atm-20-4960 |
| Indexed | SCI(E) |
| Appears in Collections: | 公共卫生学院 第三医院 |
